If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Holding(s) in Company

27 Nov 2014 14:32

RNS Number : 2169Y
Fastnet Oil & Gas PLC
27 November 2014
 

27 November 2014

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Holdings in Company

 

The Company has received notification by Pan Maghreb Oil & Gas Limited ("Pan Maghreb") of a corporate restructuring ("Restructuring") and resulting changes in its shareholding in Fastnet. Prior to the Restructuring, Pan Maghreb held 40,688,212 ordinary shares in the capital of the Company (representing 11.78% of its share capital).

 

Pan Maghreb has declared a dividend in specie ("Dividend") of its entire holding in Fastnet. The result of the dividend is that, save for Paul Griffiths (MD of Fastnet) who has waived his right to the Dividend, each of Carl Kindinger, Zizi Mahmoud and Armira Zylyftari (together the "Receiving Shareholders") now has received Fastnet shares in proportion to their shareholdings in Pan Maghreb.

 

In addition to the above, the Receiving Shareholders have also transferred their shares in Pan Maghreb back to Pan Maghreb and those shares have been cancelled, leaving Paul Griffiths as the sole shareholder of Pan Maghreb.

 

The shareholdings in Fastnet and Pan Maghreb, both before and after the Restructuring, are set out below:

 

Position prior to the Restructuring

 

Shareholder

Holding in

Pan Maghreb

"Look through" holding in Fastnet

"Look through" holding in Fastnet (%)

Paul Griffiths

37.5%

15,258,080

4.42

Armira Zylyftari

28.5%

11,596,140

3.36

Zizi Mahmoud

25.0%

10,172,053

2.95

Carl Kindinger

9.0%

3,661,939

1.06

TOTAL

100.0%

40,688,212

11.78

 

Position following the Restructuring

 

Shareholder

Direct holding in Fastnet

 

Direct holding in Fastnet (%)

Pan Maghreb*

15,258,080

4.42

Armira Zylyftari

11,596,140

3.36

Zizi Mahmoud

10,172,053

2.95

Carl Kindinger

3,661,939

1.06

TOTAL

40,688,212

11.78

 

*Paul Griffiths is the sole shareholder of Pan Maghreb

 

There is no change to Paul Griffiths' beneficial interest in Fastnet as a result of the Restructuring.

 

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

GMP Securities Europe LLP

(Joint Broker)

Rob Collins, Emily Morris, Liz Williamson

 

+44 (20) 20 7467 2800

Davy

(ESM Adviser & Joint Broker)

John Frain

Anthony Farrell

 

 +353 (1) 679 6363

Bell Pottinger

Philip Dennis, Rollo Crichton-Stuart, Jimmy Lea

 

 +44 (0) 207 861 3232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGGBPGUPCGCM
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.